Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: A meta-analysis

Journal of Gastrointestinal and Liver Diseases

Volumn 22, Issue 4, 2013, Pages 413-418

  Lee, Ju Han ^a   Kim, Younghye ^a   Choi, Jung Woo ^a   Kim, Young Sik ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Gastrointestinal stromal tumor; Imatinib; Resistance

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; STEM CELL FACTOR RECEPTOR; SUNITINIB;

ARTICLE; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; GASTROINTESTINAL STROMAL TUMOR; GENE; GENE MUTATION; GENETIC CORRELATION; GENOTYPE; HUMAN; KIT GENE; META ANALYSIS; PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA GENE; POINT MUTATION; POLYMERASE CHAIN REACTION; PREVALENCE; PUBLISHING; SEQUENCE ANALYSIS;

ANTINEOPLASTIC AGENTS; BENZAMIDES; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; EXONS; GASTROINTESTINAL STROMAL TUMORS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; ODDS RATIO; PHENOTYPE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RISK FACTORS;

EID: 84890482641     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004;22:3813-3825.
2. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-580.
3. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708-710.
4. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-566.
5. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295:139-145.
6. Judson I, Demetri G. Advances in the treatment of gastrointestinal stromal tumours. Ann Oncol 2007;18 Suppl 10:x20-24.
7. Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006;42:1093-1103.
8. Rutkowski P, Nowecki ZI, Debiec-Rychter M, et al. Predictive factors for long-term effects of imatinib therapy in patients with inoperable/ metastatic CD117(+) gastrointestinal stromal tumors (GISTs). J Cancer Res Clin Oncol 2007;133:589-597.
9. Heinrich MC, Owzar K, Corless CL, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008;26:5360-5367.
10. Sym SJ, Ryu MH, Lee JL, et al. Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs). J Surg Oncol 2008;98:27-33.
11. Li J, Gong JF, Li J, Gao J, Sun NP, Shen L. Efficacy of imatinib dose escalation in Chinese gastrointestinal stromal tumor patients. World J Gastroenterol 2012;18:698-703.
12. Antonescu CR, Besmer P, Guo T, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005;11:4182-4190.
13. Wardelmann E, Merkelbach-Bruse S, Pauls K, et al. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res 2006;12:1743-1749.
14. Wang CM, Huang K, Zhou Y, et al. Molecular mechanisms of secondary imatinib resistance in patients with gastrointestinal stromal tumors. J Cancer Res Clin Oncol 2010;136:1065-1071.
15. Yeh CN, Chen YY, Tseng JH, et al. Imatinib Mesylate for Patients with Recurrent or Metastatic Gastrointestinal Stromal Tumors Expressing KIT: A Decade Experience from Taiwan. Transl Oncol 2011;4:328-335.
16. Armbrust T, Sobotta M, Gunawan B, et al. Does imatinib turn recurrent and/or metastasized gastrointestinal stromal tumors into a chronic disease?-single center experience. Eur J Gastroenterol Hepatol 2009;21:819-823.
17. Wang WL, Conley A, Reynoso D, et al. Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor. Cancer Chemother Pharmacol 2011;67 Suppl 1:S15-24.
18. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS)for assessing the quality of nonrandomized studies in metaanalyses. 2000; http://www.ohri.ca/programs/clinical_epidemiology/ oxford.asp.
19. Lee JH, Lee ES, Kim YS. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer 2007;110:38-46.
20. Lee JH, Choi JW, Kim YS. Frequencies of BRAF and NRAS mutations are diTherent in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol 2011;164:776-784.
21. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
22. Lim KH, Huang MJ, Chen LT, et al. Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors. Med Oncol 2008;25:207-213.
23. Nishida T, Kanda T, Nishitani A, et al. Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib-resistant gastrointestinal stromal tumor. Cancer Sci 2008;99:799-804.
24. Debiec-Rychter M, Cools J, Dumez H, et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 2005;128:270-279.
25. Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006;24:4764-4774.
26. Chen P, Zong L, Zhao W, Shi L. Efficacy evaluation of imatinib treatment in patients with gastrointestinal stromal tumors: a meta-analysis. World J Gastroenterol 2010;16:4227-4232.
27. Gramza AW, Corless CL, Heinrich MC. Resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumors. Clin Cancer Res 2009;15:7510-7518.
28. Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and diTherential diagnosis. Arch Pathol Lab Med 2006;130:1466-1478.
29. Ashman LK, Griffith R. Therapeutic targeting of c-KIT in cancer. Expert Opin Investig Drugs 2013;22:103-115.
30. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour aTher failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329-1338.
31. Tan CB, Zhi W, Shahzad G, Mustacchia P. Gastrointestinal stromal tumors: a review of case reports, diagnosis, treatment, and future directions. ISRN Gastroenterol 2012;2012:595968.